Disclosure Sufficiency and Support

An invention is operative if it works for its intended use. The standard is whether a PHOSITA, in view of the specification, can clearly identify the operative embodiments that fall within the claim scope without undue experimentation.

Key requirements:

• A claim should recite the manner in which elements cooperate or interact
• A claim is inoperative when it requires an unattainable result
• Functional claims claiming only the result itself should be amended

The specification should disclose why the invention is useful and make its usefulness apparent to the skilled person. The utility standard is lower than the reasonable expectation of success test used in obviousness analysis.

Key considerations:

• Inventions for medical use are presumed useful
• Credibility is assessed from the perspective of a PHOSITA
• A credible assertion of specific and substantial utility should be provided for each independent claim
• Commercial utility is not required
• In the U.S., human clinical trial data is not required for medical inventions
• In Europe, clinical trial data may be required to establish utility for treatment inventions

Plausibility sits close to utility but carries a stronger European emphasis. The core question is whether the specification gives a credible technical basis for the asserted effect or result. This is a low-threshold test, lower than the reasonable expectation of success test used in obviousness analysis.

Plausibility is not a distinct condition of validity, but one element in the test of sufficiency. It addresses whether the application, together with common general knowledge, renders it sufficiently plausible that a technical effect associated with the claimed invention is actually achieved.

The Agrevo materials capture a narrower European thread related to technical contribution and whether the asserted effect is plausible across the claim scope. Where the technical contribution is not plausible across the full scope of the claims, the claims may be found insufficient and/or obvious on the AgrEvo basis.

Classical sufficiency addresses whether the application teaches the invention clearly and completely enough for the skilled person to carry it out across the relevant claim scope. The scope of the claims must be commensurate with the technical effects that the inventor is relying on to support the assertion that an invention has been made.

Two-stage test:

1. Determine whether the disclosure, read in light of common general knowledge, makes it plausible that the invention will work across the scope of the claim
2. Consider whether evidence establishes that the invention cannot be performed across the scope without undue burden

Biogen insufficiency captures a narrower insufficiency concept associated with claims that overreach relative to what the specification actually teaches. A patent may be revoked where the specification does not disclose the invention clearly and completely enough for it to be performed across the full ambit of the claim.

Enablement spans Europe, the United States, and parts of Asia. It focuses on whether the specification enables the full claimed scope without undue experimentation, with substantial attention to predictability versus unpredictability across fields.

The specification must allow a person of ordinary skill in the art to make and use the full scope of the claimed invention without undue experimentation. The level of detail required depends on whether the art is predictable or unpredictable.

Predictability varies by field:

• Unpredictable arts: Antibodies, biotechnology, chemistry — require detailed disclosure
• Predictable arts: Mechanical systems, electrical circuits — may require less detail

The best-mode requirement is a U.S. disclosure obligation. It reflects one of the traditional disclosure-related expectations in U.S. practice and is generally considered a low standard in biomedical inventions.